Jump to content

Lisuride: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Pentagron (talk | contribs)
300 edits
Sort cat.
 
(9 intermediate revisions by 8 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| Watchedfields = changed
| Watchedfields = changed
Line 16: Line 17:
| pregnancy_US =
| pregnancy_US =
| pregnancy_category =
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_BR = C1
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_EU =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_status = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]<ref name="pmid30805732" /><br />''Investigational:'' [[Subcutaneous implant]], [[transdermal patch]]<ref name="pmid30805732" />
| routes_of_administration = [[Oral administration|Oral]]<ref name="pmid30805732" /><br />''Investigational:'' [[Subcutaneous implant]], [[transdermal patch]]<ref name="pmid30805732" />
Line 58: Line 69:
}}
}}


'''Lisuride''', sold under the brand name '''Dopergin''' among others, is a [[monoaminergic]] [[drug|medication]] of the [[ergoline]] class which is used in the treatment of [[Parkinson's disease]], [[migraine]], and [[hyperprolactinemia|high prolactin levels]].<ref name="pmid30805732">{{cite journal | vauthors = Horowski R, Löschmann PA | title = Classical dopamine agonists | journal = Journal of Neural Transmission | volume = 126 | issue = 4 | pages = 449–454 | date = April 2019 | pmid = 30805732 | doi = 10.1007/s00702-019-01989-y | s2cid = 71144049 }}</ref> It is taken [[oral administration|by mouth]].<ref name="pmid30805732" />
'''Lisuride''', sold under the brand name '''Dopergin''' among others, is a [[monoaminergic]] [[drug|medication]] of the [[ergoline]] class which is used in the treatment of [[Parkinson's disease]], [[migraine]], and [[hyperprolactinemia|high prolactin levels]].<ref name="pmid30805732">{{cite journal | vauthors = Horowski R, Löschmann PA | title = Classical dopamine agonists | journal = Journal of Neural Transmission | volume = 126 | issue = 4 | pages = 449–454 | date = April 2019 | pmid = 30805732 | doi = 10.1007/s00702-019-01989-y | s2cid = 71144049 | doi-access = free }}</ref> It is taken [[oral administration|by mouth]].<ref name="pmid30805732" />


[[Side effect]]s of lisuride include [[nausea]] and vomiting,
[[Side effect]]s of lisuride include [[nausea]] and vomiting,
Line 64: Line 75:
[[fatigue]] or [[drowsiness]],
[[fatigue]] or [[drowsiness]],
[[insomnia]] or sleep, gastrointestinal disturbances such as [[abdominal pain]] or [[diarrhea]],
[[insomnia]] or sleep, gastrointestinal disturbances such as [[abdominal pain]] or [[diarrhea]],
nasal congestion or runny nose, and [[hypotension]], [[hallucinations]] or [[confusion]] (particularly at higher doses). Rarely, serious side effects such as [[cardiac fibrosis|cardiac]] or [[pulmonary fibrosis]] have been reported with long-term use, but they are extremely uncommon.<ref name="MoveDisord2002" /><ref>{{cite journal|title=Lisuride for Parkinson's disease: A critical review of the literature|journal=Expert Opinion on Drug Safety|volume=10|issue=4|pages=543-551|year=2011|doi=10.1517/14740338.2011.565179}}</ref>
nasal congestion or runny nose, and [[hypotension]], [[hallucinations]] or [[confusion]] (particularly at higher doses). Rarely, serious side effects such as [[cardiac fibrosis|cardiac]] or [[pulmonary fibrosis]] have been reported with long-term use, but they are extremely uncommon.<ref name="MoveDisord2002" />


Lisuride acts as a mixed [[agonist]] and [[receptor antagonist|antagonist]] of [[dopamine receptor|dopamine]], [[serotonin receptor|serotonin]], and [[adrenergic receptor]]s.<ref name="pmid30805732" /><ref name="pmid12388666" /><ref name="pmid12388667" /><ref name="pmid12388668" /> Activation of specific dopamine receptors is thought to be responsible for its effectiveness in the treatment of Parkinson's disease and ability to suppress [[prolactin]] levels,<ref name="pmid30805732" /> while interactions with serotonin receptors are thought to be principally involved in its effectiveness for [[migraine]].<ref name="pmid23815106">{{cite journal | vauthors = Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A | title = Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs | journal = Expert Opinion on Pharmacotherapy | volume = 14 | issue = 12 | pages = 1599–1610 | date = August 2013 | pmid = 23815106 | doi = 10.1517/14656566.2013.806487 | s2cid = 22721405 }}</ref><ref name="pmid27465216">{{cite journal | vauthors = Villalón CM, VanDenBrink AM | title = The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments | journal = Mini Reviews in Medicinal Chemistry | volume = 17 | issue = 11 | pages = 928–938 | date = 2017 | pmid = 27465216 | doi = 10.2174/1389557516666160728121050 }}</ref>
Lisuride acts as a mixed [[agonist]] and [[receptor antagonist|antagonist]] of [[dopamine receptor|dopamine]], [[serotonin receptor|serotonin]], and [[adrenergic receptor]]s.<ref name="pmid30805732" /><ref name="pmid12388666" /><ref name="pmid12388667" /><ref name="pmid12388668" /> Activation of specific dopamine receptors is thought to be responsible for its effectiveness in the treatment of Parkinson's disease and ability to suppress [[prolactin]] levels,<ref name="pmid30805732" /> while interactions with serotonin receptors are thought to be principally involved in its effectiveness for [[migraine]].<ref name="pmid23815106">{{cite journal | vauthors = Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A | title = Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs | journal = Expert Opinion on Pharmacotherapy | volume = 14 | issue = 12 | pages = 1599–1610 | date = August 2013 | pmid = 23815106 | doi = 10.1517/14656566.2013.806487 | s2cid = 22721405 }}</ref><ref name="pmid27465216">{{cite journal | vauthors = Villalón CM, VanDenBrink AM | title = The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments | journal = Mini Reviews in Medicinal Chemistry | volume = 17 | issue = 11 | pages = 928–938 | date = 2017 | pmid = 27465216 | doi = 10.2174/1389557516666160728121050 }}</ref>
Line 79: Line 90:
Lisuride is a [[ligand (chemistry)|ligand]] of [[dopamine receptor|dopamine]], [[serotonin receptor|serotonin]], and [[adrenergic receptor]]s as well as the [[histamine H1 receptor|histamine H<sub>1</sub> receptor]].<ref name="pmid12388666">{{cite journal | vauthors = Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 791–804 | date = November 2002 | pmid = 12388666 | doi = 10.1124/jpet.102.039867 | s2cid = 6200455 }}</ref> It has sub-[[nanomolar]] [[affinity (pharmacology)|affinity]] for the dopamine [[D2 receptor|D<sub>2</sub>]], and [[D3 receptor|D<sub>3</sub> receptor]]s, serotonin [[5-HT1A receptor|5-HT<sub>1A</sub>]] and [[5-HT1D receptor|5-HT<sub>1D</sub> receptor]]s, and [[α2A-adrenergic receptor|α<sub>2A</sub>-]], [[α2B-adrenergic receptor|α<sub>2B</sub>-]], and [[α2C-adrenergic receptor|α<sub>2C</sub>-adrenergic receptor]]s, and low-nanomolar affinity for the dopamine [[D1 receptor|D<sub>1</sub>]], [[D4 receptor|D<sub>4</sub>]], and [[D5 receptor|D<sub>5</sub> receptor]]s, serotonin [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s, [[α1A-adrenergic receptor|α<sub>1A</sub>-]], [[α1B-adrenergic receptor|α<sub>1B</sub>-]], and [[α1D-adrenergic receptor|α<sub>1D</sub>-adrenergic receptor]]s, and histamine H<sub>1</sub> receptor.<ref name="pmid12388666" /><ref name="pmid12373423">{{cite journal | vauthors = Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE | title = Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats | journal = Psychopharmacology | volume = 164 | issue = 1 | pages = 93–107 | date = October 2002 | pmid = 12373423 | doi = 10.1007/s00213-002-1141-z | s2cid = 19825878 }}</ref><ref name="pmid9600588">{{cite journal | vauthors = Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M | title = Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors | journal = Psychopharmacology | volume = 136 | issue = 4 | pages = 409–414 | date = April 1998 | pmid = 9600588 | doi = 10.1007/s002130050585 | s2cid = 3021798 }}</ref> Lisuride is a [[partial agonist]] of the D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>5A</sub>, and H<sub>1</sub> receptors, a [[full agonist|full or near-full agonist]] of the 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, and 5-HT<sub>1D</sub> receptors, and a [[silent antagonist]] of the 5-HT<sub>2B</sub> receptor and α<sub>1A</sub>-, α<sub>2A</sub>-, α<sub>2B</sub>-, and α<sub>2C</sub>-adrenergic receptors.<ref name="pmid12388667">{{cite journal | vauthors = Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 805–814 | date = November 2002 | pmid = 12388667 | doi = 10.1124/jpet.102.039875 | s2cid = 35238120 }}</ref><ref name="pmid12388668">{{cite journal | vauthors = Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 815–822 | date = November 2002 | pmid = 12388668 | doi = 10.1124/jpet.102.039883 | s2cid = 19260572 }}</ref><ref name="pmid9600588" /><ref name="pmid16614540">{{cite journal | vauthors = Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B | display-authors = 6 | title = Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis | journal = Clinical Neuropharmacology | volume = 29 | issue = 2 | pages = 80–86 | year = 2006 | pmid = 16614540 | doi = 10.1097/00002826-200603000-00005 | s2cid = 33849447 }}</ref><ref name="pmid14978232">{{cite journal | vauthors = Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M, Hacksell U, Timmerman H, Brann MR, Leurs R | display-authors = 6 | title = 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist | journal = Molecular Pharmacology | volume = 65 | issue = 3 | pages = 538–549 | date = March 2004 | pmid = 14978232 | doi = 10.1124/mol.65.3.538 | s2cid = 19140579 }}</ref><ref name=":0">{{cite journal | vauthors = Zhang S, Chen H, Zhang C, Yang Y, Popov P, Liu J, Krumm BE, Cao C, Kim K, Xiong Y, Katritch V, Shoichet BK, Jin J, Fay JF, Roth BL | display-authors = 6 | title = Inactive and active state structures template selective tools for the human 5-HT<sub>5A</sub> receptor | journal = Nature Structural & Molecular Biology | volume = 29 | issue = 7 | pages = 677–687 | date = July 2022 | pmid = 35835867 | pmc = 9299520 | doi = 10.1038/s41594-022-00796-6 }}</ref> Due to its highly non-[[binding selectivity|selective]] pharmacological activity, lisuride is described as a "dirty drug".<ref name="pmid30805732" /> The effectiveness of lisuride in Parkinson's disease and hyperprolactinemia is thought to be mostly due to activation of dopamine D<sub>2</sub> receptors.<ref name="pmid30805732" />
Lisuride is a [[ligand (chemistry)|ligand]] of [[dopamine receptor|dopamine]], [[serotonin receptor|serotonin]], and [[adrenergic receptor]]s as well as the [[histamine H1 receptor|histamine H<sub>1</sub> receptor]].<ref name="pmid12388666">{{cite journal | vauthors = Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 791–804 | date = November 2002 | pmid = 12388666 | doi = 10.1124/jpet.102.039867 | s2cid = 6200455 }}</ref> It has sub-[[nanomolar]] [[affinity (pharmacology)|affinity]] for the dopamine [[D2 receptor|D<sub>2</sub>]], and [[D3 receptor|D<sub>3</sub> receptor]]s, serotonin [[5-HT1A receptor|5-HT<sub>1A</sub>]] and [[5-HT1D receptor|5-HT<sub>1D</sub> receptor]]s, and [[α2A-adrenergic receptor|α<sub>2A</sub>-]], [[α2B-adrenergic receptor|α<sub>2B</sub>-]], and [[α2C-adrenergic receptor|α<sub>2C</sub>-adrenergic receptor]]s, and low-nanomolar affinity for the dopamine [[D1 receptor|D<sub>1</sub>]], [[D4 receptor|D<sub>4</sub>]], and [[D5 receptor|D<sub>5</sub> receptor]]s, serotonin [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s, [[α1A-adrenergic receptor|α<sub>1A</sub>-]], [[α1B-adrenergic receptor|α<sub>1B</sub>-]], and [[α1D-adrenergic receptor|α<sub>1D</sub>-adrenergic receptor]]s, and histamine H<sub>1</sub> receptor.<ref name="pmid12388666" /><ref name="pmid12373423">{{cite journal | vauthors = Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE | title = Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats | journal = Psychopharmacology | volume = 164 | issue = 1 | pages = 93–107 | date = October 2002 | pmid = 12373423 | doi = 10.1007/s00213-002-1141-z | s2cid = 19825878 }}</ref><ref name="pmid9600588">{{cite journal | vauthors = Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M | title = Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors | journal = Psychopharmacology | volume = 136 | issue = 4 | pages = 409–414 | date = April 1998 | pmid = 9600588 | doi = 10.1007/s002130050585 | s2cid = 3021798 }}</ref> Lisuride is a [[partial agonist]] of the D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>5A</sub>, and H<sub>1</sub> receptors, a [[full agonist|full or near-full agonist]] of the 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, and 5-HT<sub>1D</sub> receptors, and a [[silent antagonist]] of the 5-HT<sub>2B</sub> receptor and α<sub>1A</sub>-, α<sub>2A</sub>-, α<sub>2B</sub>-, and α<sub>2C</sub>-adrenergic receptors.<ref name="pmid12388667">{{cite journal | vauthors = Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 805–814 | date = November 2002 | pmid = 12388667 | doi = 10.1124/jpet.102.039875 | s2cid = 35238120 }}</ref><ref name="pmid12388668">{{cite journal | vauthors = Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ | title = Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 303 | issue = 2 | pages = 815–822 | date = November 2002 | pmid = 12388668 | doi = 10.1124/jpet.102.039883 | s2cid = 19260572 }}</ref><ref name="pmid9600588" /><ref name="pmid16614540">{{cite journal | vauthors = Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B | display-authors = 6 | title = Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis | journal = Clinical Neuropharmacology | volume = 29 | issue = 2 | pages = 80–86 | year = 2006 | pmid = 16614540 | doi = 10.1097/00002826-200603000-00005 | s2cid = 33849447 }}</ref><ref name="pmid14978232">{{cite journal | vauthors = Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M, Hacksell U, Timmerman H, Brann MR, Leurs R | display-authors = 6 | title = 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist | journal = Molecular Pharmacology | volume = 65 | issue = 3 | pages = 538–549 | date = March 2004 | pmid = 14978232 | doi = 10.1124/mol.65.3.538 | s2cid = 19140579 }}</ref><ref name=":0">{{cite journal | vauthors = Zhang S, Chen H, Zhang C, Yang Y, Popov P, Liu J, Krumm BE, Cao C, Kim K, Xiong Y, Katritch V, Shoichet BK, Jin J, Fay JF, Roth BL | display-authors = 6 | title = Inactive and active state structures template selective tools for the human 5-HT<sub>5A</sub> receptor | journal = Nature Structural & Molecular Biology | volume = 29 | issue = 7 | pages = 677–687 | date = July 2022 | pmid = 35835867 | pmc = 9299520 | doi = 10.1038/s41594-022-00796-6 }}</ref> Due to its highly non-[[binding selectivity|selective]] pharmacological activity, lisuride is described as a "dirty drug".<ref name="pmid30805732" /> The effectiveness of lisuride in Parkinson's disease and hyperprolactinemia is thought to be mostly due to activation of dopamine D<sub>2</sub> receptors.<ref name="pmid30805732" />


While lisuride has a similar receptor binding profile to the more well-known and chemically similar ergoline [[lysergic acid diethylamide]] (LSD; ''N'',''N''-diethyllysergamide) and acts as a partial agonist of the serotonin 5-HT<sub>2A</sub> receptor likewise,<ref name="pmid12388668" /> it lacks the [[psychedelic drug|psychedelic]] effects of LSD.<ref name="pmid30805732" /> Research suggests that the lack of psychedelic effects with lisuride arises from [[functional selectivity|biased agonism]] of the 5-HT<sub>2A</sub> receptor. Stimulation of the 5-HT<sub>2A</sub> [[GPCR oligomer|protomer]] within the [[5-HT2A receptor|5-HT<sub>2A</sub>]]–[[Glutamate receptor#Metabotropic glutamate receptors|mGlu2]] [[GPCR oligomer|receptor complex]] evokes psychedelic effects, while these effects do not occur during sole stimulation of [[monomer]]ic 5-HT<sub>2A</sub> receptors. Accordingly, different [[G protein]]s are involved.<ref>{{cite journal | vauthors = Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J | title = Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists | journal = Neuroscience Letters | volume = 493 | issue = 3 | pages = 76–79 | date = April 2011 | pmid = 21276828 | pmc = 3064746 | doi = 10.1016/j.neulet.2011.01.046 }}</ref><ref>{{cite journal | vauthors = González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC | display-authors = 6 | title = Identification of a serotonin/glutamate receptor complex implicated in psychosis | journal = Nature | volume = 452 | issue = 7183 | pages = 93–97 | date = March 2008 | pmid = 18297054 | pmc = 2743172 | doi = 10.1038/nature06612 | bibcode = 2008Natur.452...93G }}</ref> Lisuride behaves as an agonist at the 5-HT<sub>2A</sub> receptor monomer. Since it [[competitive antagonist|competitively antagonizes]] the effects of LSD, it may be regarded as a protomer antagonist of the 5-HT<sub>2A</sub>–mGluR [[heteromer]].<ref>{{cite journal | vauthors = González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA | display-authors = 6 | title = Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | journal = Neuron | volume = 53 | issue = 3 | pages = 439–452 | date = February 2007 | pmid = 17270739 | doi = 10.1016/j.neuron.2007.01.008 | s2cid = 16309730 | doi-access = free }}</ref> [[GPCR oligomer]]s are discrete entities and usually possess properties distinct from their parent monomeric receptors.
While lisuride has a similar receptor binding profile to the more well-known and chemically similar ergoline [[lysergic acid diethylamide]] (LSD; ''N'',''N''-diethyllysergamide) and acts as a partial agonist of the serotonin 5-HT<sub>2A</sub> receptor likewise,<ref name="pmid12388668" /> it lacks the [[psychedelic drug|psychedelic]] effects of LSD and hence is non-[[hallucinogen]]ic.<ref name="DuanCaoWang2024">{{cite journal | vauthors = Duan W, Cao D, Wang S, Cheng J | title = Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants | journal = Chem Rev | volume = 124 | issue = 1 | pages = 124–163 | date = January 2024 | pmid = 38033123 | doi = 10.1021/acs.chemrev.3c00375 | url = }}</ref><ref name="pmid30805732" /> Research suggests that the lack of psychedelic effects with lisuride arises from [[functional selectivity|biased agonism]] of the 5-HT<sub>2A</sub> receptor. Stimulation of the 5-HT<sub>2A</sub> [[GPCR oligomer|protomer]] within the [[5-HT2A receptor|5-HT<sub>2A</sub>]]–[[Glutamate receptor#Metabotropic glutamate receptors|mGlu2]] [[GPCR oligomer|receptor complex]] evokes psychedelic effects, while these effects do not occur during sole stimulation of [[monomer]]ic 5-HT<sub>2A</sub> receptors. Accordingly, different [[G protein]]s are involved.<ref>{{cite journal | vauthors = Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J | title = Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists | journal = Neuroscience Letters | volume = 493 | issue = 3 | pages = 76–79 | date = April 2011 | pmid = 21276828 | pmc = 3064746 | doi = 10.1016/j.neulet.2011.01.046 }}</ref><ref>{{cite journal | vauthors = González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC | display-authors = 6 | title = Identification of a serotonin/glutamate receptor complex implicated in psychosis | journal = Nature | volume = 452 | issue = 7183 | pages = 93–97 | date = March 2008 | pmid = 18297054 | pmc = 2743172 | doi = 10.1038/nature06612 | bibcode = 2008Natur.452...93G }}</ref> Lisuride behaves as an agonist at the 5-HT<sub>2A</sub> receptor monomer. Since it [[competitive antagonist|competitively antagonizes]] the effects of LSD, it may be regarded as a protomer antagonist of the 5-HT<sub>2A</sub>–mGluR [[heteromer]].<ref>{{cite journal | vauthors = González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA | display-authors = 6 | title = Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | journal = Neuron | volume = 53 | issue = 3 | pages = 439–452 | date = February 2007 | pmid = 17270739 | doi = 10.1016/j.neuron.2007.01.008 | s2cid = 16309730 | doi-access = free }}</ref> [[GPCR oligomer]]s are discrete entities and usually possess properties distinct from their parent monomeric receptors.


Lisuride dose-dependently suppresses [[prolactin]] levels due to its dopaminergic activity.<ref name="pmid30805732" /><ref name="pmid30852578">{{cite journal | vauthors = Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A | title = Dopamine Agonists: From the 1970s to Today | journal = Neuroendocrinology | volume = 109 | issue = 1 | pages = 34–41 | date = 2019 | pmid = 30852578 | doi = 10.1159/000499470 | doi-access = free }}</ref> As an antagonist of the 5-HT<sub>2B</sub> receptor, lisuride has no risk of [[cardiac valvulopathy]] in contrast to related ergolines like [[pergolide]] and [[cabergoline]].<ref name="pmid30805732" />
Lisuride dose-dependently suppresses [[prolactin]] levels due to its dopaminergic activity.<ref name="pmid30805732" /><ref name="pmid30852578">{{cite journal | vauthors = Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A | title = Dopamine Agonists: From the 1970s to Today | journal = Neuroendocrinology | volume = 109 | issue = 1 | pages = 34–41 | date = 2019 | pmid = 30852578 | doi = 10.1159/000499470 | doi-access = free }}</ref> As an antagonist of the 5-HT<sub>2B</sub> receptor, lisuride has no risk of [[cardiac valvulopathy]] in contrast to related ergolines like [[pergolide]] and [[cabergoline]].<ref name="pmid30805732" />


Minute amounts of lisuride suppress the firing of dorsal raphe serotonergic neurons, presumably due to agonist activity at 5-HT<sub>1A</sub> receptors. <ref>{{cite journal | vauthors = Rogawski MA, Aghajanian GK | title = Response of central monoaminergic neurons to lisuride: comparison with LSD | journal = Life Sci. |volume = 24 | issue = 14 | pages = 1289-1297 | date = 1979 | pmid = 470543 | doi = 10.1016/0024-3205(79)90148-6 }}</ref> Noradrenergic neurons of the locus coeruleus were accelerated by the drug at somewhat higher doses. Pars compacta dopamine neurons demonstrated a variable response.
Minute amounts of lisuride suppress the firing of dorsal raphe serotonergic neurons, presumably due to agonist activity at 5-HT<sub>1A</sub> receptors. <ref>{{cite journal | vauthors = Rogawski MA, Aghajanian GK | title = Response of central monoaminergic neurons to lisuride: comparison with LSD | journal = Life Sci. |volume = 24 | issue = 14 | pages = 1289–1297 | date = 1979 | pmid = 470543 | doi = 10.1016/0024-3205(79)90148-6 }}</ref> Noradrenergic neurons of the locus coeruleus were accelerated by the drug at somewhat higher doses, consistent with α<sub>1</sub>-adrenergic receptor antagonist activity. Pars compacta dopamine neurons demonstrated a variable response.


{| class="wikitable"
{| class="wikitable"
Line 235: Line 246:


===Availability===
===Availability===
Lisuride was previously more widely available throughout the world,<ref name="IndexNominum2000" /><ref name="pmid30805732" /> but as of 2020 it appears to be marketed only in [[Egypt]], [[France]], [[Italy]], [[Kuwait]], [[Lebanon]], [[Mexico]], [[New Zealand]], and [[Pakistan]].<ref name="Drugs.com" /> Lisuride is not currently available in the [[United States]], as the drug was not a commercial success in comparison with other dopamine receptor agonists.{{Citation needed|date=April 2021}}
Lisuride was previously more widely available throughout the world,<ref name="IndexNominum2000" /><ref name="pmid30805732" /> but as of 2020 it appears to be marketed only in [[Egypt]], [[France]], [[Italy]], [[Kuwait]], [[Lebanon]], [[Mexico]], [[New Zealand]], and [[Pakistan]].<ref name="Drugs.com" /> Lisuride is not currently available in the [[United States]], as the drug was not a commercial success.


==Research==
==Research==
Line 272: Line 283:
[[Category:Ergolines]]
[[Category:Ergolines]]
[[Category:Histamine agonists]]
[[Category:Histamine agonists]]
[[Category:Non-hallucinogenic 5-HT2A receptor agonists]]
[[Category:Prolactin inhibitors]]
[[Category:Prolactin inhibitors]]
[[Category:Serotonin receptor antagonists]]
[[Category:Serotonin receptor antagonists]]

Latest revision as of 00:27, 26 October 2024

Lisuride
Clinical data
Trade namesDopergin, others
Other namesLysuride; Mesorgydin; Methylergol carbamide
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral[1]
Investigational: Subcutaneous implant, transdermal patch[1]
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability10–20%[3]
Protein binding60–70%[3]
MetabolismHepatic
MetabolitesMore than 15 known[3]
Elimination half-life2 hours[3]
ExcretionRenal and biliary in equal amounts
Identifiers
  • 1,1-Diethyl-3-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-urea
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.038.099 Edit this at Wikidata
Chemical and physical data
FormulaC20H26N4O
Molar mass338.455 g·mol−1
3D model (JSmol)
  • [H][C@@]12Cc3c[nH]c4cccc(C1=C[C@H](NC(=O)N(CC)CC)CN2C)c34
  • InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1 checkY
  • Key:BKRGVLQUQGGVSM-KBXCAEBGSA-N checkY
  (verify)

Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline class which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels.[1] It is taken by mouth.[1]

Side effects of lisuride include nausea and vomiting, dizziness, headache, fatigue or drowsiness, insomnia or sleep, gastrointestinal disturbances such as abdominal pain or diarrhea, nasal congestion or runny nose, and hypotension, hallucinations or confusion (particularly at higher doses). Rarely, serious side effects such as cardiac or pulmonary fibrosis have been reported with long-term use, but they are extremely uncommon.[3]

Lisuride acts as a mixed agonist and antagonist of dopamine, serotonin, and adrenergic receptors.[1][4][5][6] Activation of specific dopamine receptors is thought to be responsible for its effectiveness in the treatment of Parkinson's disease and ability to suppress prolactin levels,[1] while interactions with serotonin receptors are thought to be principally involved in its effectiveness for migraine.[7][8]

Medical uses

[edit]

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks.[1] The use of lisuride as initial antiparkinsonian medication for Parkinson's disease has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the parkinsonian symptoms.[1][additional citation(s) needed] Evidence is insufficient to support lisuride in the treatment of advanced Parkinson's disease as an alternative to levodopa or bromocriptine.[9][10]

Side effects

[edit]

Side effects of lisuride include nausea and lowered blood pressure, among others.[3]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Lisuride is a ligand of dopamine, serotonin, and adrenergic receptors as well as the histamine H1 receptor.[4] It has sub-nanomolar affinity for the dopamine D2, and D3 receptors, serotonin 5-HT1A and 5-HT1D receptors, and α2A-, α2B-, and α2C-adrenergic receptors, and low-nanomolar affinity for the dopamine D1, D4, and D5 receptors, serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, α1A-, α1B-, and α1D-adrenergic receptors, and histamine H1 receptor.[4][11][12] Lisuride is a partial agonist of the D2, D3, D4, 5-HT2A, 5-HT2C, 5-HT5A, and H1 receptors, a full or near-full agonist of the 5-HT1A, 5-HT1B, and 5-HT1D receptors, and a silent antagonist of the 5-HT2B receptor and α1A-, α2A-, α2B-, and α2C-adrenergic receptors.[5][6][12][13][14][15] Due to its highly non-selective pharmacological activity, lisuride is described as a "dirty drug".[1] The effectiveness of lisuride in Parkinson's disease and hyperprolactinemia is thought to be mostly due to activation of dopamine D2 receptors.[1]

While lisuride has a similar receptor binding profile to the more well-known and chemically similar ergoline lysergic acid diethylamide (LSD; N,N-diethyllysergamide) and acts as a partial agonist of the serotonin 5-HT2A receptor likewise,[6] it lacks the psychedelic effects of LSD and hence is non-hallucinogenic.[16][1] Research suggests that the lack of psychedelic effects with lisuride arises from biased agonism of the 5-HT2A receptor. Stimulation of the 5-HT2A protomer within the 5-HT2A–mGlu2 receptor complex evokes psychedelic effects, while these effects do not occur during sole stimulation of monomeric 5-HT2A receptors. Accordingly, different G proteins are involved.[17][18] Lisuride behaves as an agonist at the 5-HT2A receptor monomer. Since it competitively antagonizes the effects of LSD, it may be regarded as a protomer antagonist of the 5-HT2A–mGluR heteromer.[19] GPCR oligomers are discrete entities and usually possess properties distinct from their parent monomeric receptors.

Lisuride dose-dependently suppresses prolactin levels due to its dopaminergic activity.[1][20] As an antagonist of the 5-HT2B receptor, lisuride has no risk of cardiac valvulopathy in contrast to related ergolines like pergolide and cabergoline.[1]

Minute amounts of lisuride suppress the firing of dorsal raphe serotonergic neurons, presumably due to agonist activity at 5-HT1A receptors. [21] Noradrenergic neurons of the locus coeruleus were accelerated by the drug at somewhat higher doses, consistent with α1-adrenergic receptor antagonist activity. Pars compacta dopamine neurons demonstrated a variable response.

Activities of lisuride at various sites[4][5][6][14][22]
Site Affinity (Ki [nM]) Efficacy (Emax [%]) Action
D1 65 ? ?
D2S 0.34 55 Partial agonist
D2L 0.66 21 Partial agonist
D3 0.28 49 Partial agonist
D4 4.6 32 Partial agonist
D5 3.5 ? ?
5-HT1A 0.15 98 Full agonist
5-HT1B 19 85 Partial agonist
5-HT1D 0.98 81 Partial agonist
5-HT2A 2.8 52 Partial agonist
5-HT2B 1.3 0 Silent antagonist
5-HT2C 6.6 75 Partial agonist
5-HT5A ? 11[15] Partial agonist[15]
α1A 5.5 0 Silent antagonist
α1B 17 ? ?
α1D 3.0 ? ?
α2A 0.055 0 Silent antagonist
α2B 0.13 0 Silent antagonist
α2C 0.13 0 Silent antagonist
α2D 0.79 ? ?
β1 68 ? ?
β2 7.9 ? ?
H1 35 ? Partial agonist
M1 >10,000 – –
Notes: All receptors are human except α2D-adrenergic, which is rat (no human counterpart).[4]

Pharmacokinetics

[edit]

Absorption of lisuride from the gastrointestinal tract with oral administration is complete.[3] The absolute bioavailability of lisuride is 10 to 20% due to high first-pass metabolism.[3] The plasma protein binding of lisuride is 60 to 70%.[3] Peak levels of lisuride occur 60 to 80 minutes after ingestion with high variability between individuals.[3] The elimination half-life of lisuride is approximately 2 hours.[3] This is shorter than most other dopamine agonists.[3] Lisuride has more than 15 known metabolites.[3]

Chemistry

[edit]

Lisuride is described as the free base and as the hydrogen maleate salt.[23][24][25]

Bromination of lisuride gives bromerguride (2-bromolisuride), which has a "reversed pharmacodynamic profile" compared to that of lisuride.[26]

History

[edit]

Lisuride was synthesized by Zikán and Semonský at the Research Institute for Pharmacy and Biochemistry at Prague (later SPOFA) as an antimigraine agent analogous to methysergide and was described in 1960.[1][27] It was marketed by the early 1970s.[28]

Society and culture

[edit]

Generic names

[edit]

Lisuride is the INNTooltip International Nonproprietary Name and lysuride is the BANTooltip British Approved Name.[23][29][24][25]

Brand names

[edit]

Lisuride has been sold under brand names including Arolac, Cuvalit, Dopagon, Dopergin, Dopergine, Eunal, Lisenil, Lizenil, Lysenyl, Proclacam, Prolacam, and Revanil.[23][24][25][1]

Availability

[edit]

Lisuride was previously more widely available throughout the world,[24][1] but as of 2020 it appears to be marketed only in Egypt, France, Italy, Kuwait, Lebanon, Mexico, New Zealand, and Pakistan.[25] Lisuride is not currently available in the United States, as the drug was not a commercial success.

Research

[edit]

Preliminary clinical research suggests that transdermal administration of lisuride may be useful in the treatment of Parkinson's disease.[1] As lisuride has poor bioavailability when taken orally and has a short half-life, continuous transdermal administration offers significant advantages and could make the compound a much more consistent therapeutic agent.[1] Lisuride was under development as a transdermal patch and subcutaneous implant for the treatment of Parkinson's disease, restless legs syndrome, and dyskinesias in the 2000s and 2010s, but development was discontinued.[30][31]

References

[edit]
  1. ^ a b c d e f g h i j k l m n o p q r Horowski R, Löschmann PA (April 2019). "Classical dopamine agonists". Journal of Neural Transmission. 126 (4): 449–454. doi:10.1007/s00702-019-01989-y. PMID 30805732. S2CID 71144049.
  2. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  3. ^ a b c d e f g h i j k l m "DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease". Movement Disorders. 17 Suppl 4 (S4): S74 – S78. 2002. doi:10.1002/mds.5565. PMID 12211144. S2CID 79230929.
  4. ^ a b c d e Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
  5. ^ a b c Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
  6. ^ a b c d Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 815–822. doi:10.1124/jpet.102.039883. PMID 12388668. S2CID 19260572.
  7. ^ Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A (August 2013). "Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs". Expert Opinion on Pharmacotherapy. 14 (12): 1599–1610. doi:10.1517/14656566.2013.806487. PMID 23815106. S2CID 22721405.
  8. ^ Villalón CM, VanDenBrink AM (2017). "The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments". Mini Reviews in Medicinal Chemistry. 17 (11): 928–938. doi:10.2174/1389557516666160728121050. PMID 27465216.
  9. ^ Clarke CE, Speller JM (2000). "Lisuride for levodopa-induced complications in Parkinson's disease". The Cochrane Database of Systematic Reviews. 1999 (2): CD001515. doi:10.1002/14651858.CD001515. PMC 7025784. PMID 10796801.
  10. ^ Clarke CE, Speller JM (2000). "Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease". The Cochrane Database of Systematic Reviews. 1999 (2): CD001514. doi:10.1002/14651858.CD001514. PMC 7028005. PMID 10796800.
  11. ^ Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (October 2002). "Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats". Psychopharmacology. 164 (1): 93–107. doi:10.1007/s00213-002-1141-z. PMID 12373423. S2CID 19825878.
  12. ^ a b Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). "Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors". Psychopharmacology. 136 (4): 409–414. doi:10.1007/s002130050585. PMID 9600588. S2CID 3021798.
  13. ^ Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, et al. (2006). "Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis". Clinical Neuropharmacology. 29 (2): 80–86. doi:10.1097/00002826-200603000-00005. PMID 16614540. S2CID 33849447.
  14. ^ a b Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M, et al. (March 2004). "8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist". Molecular Pharmacology. 65 (3): 538–549. doi:10.1124/mol.65.3.538. PMID 14978232. S2CID 19140579.
  15. ^ a b c Zhang S, Chen H, Zhang C, Yang Y, Popov P, Liu J, et al. (July 2022). "Inactive and active state structures template selective tools for the human 5-HT5A receptor". Nature Structural & Molecular Biology. 29 (7): 677–687. doi:10.1038/s41594-022-00796-6. PMC 9299520. PMID 35835867.
  16. ^ Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123.
  17. ^ Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (April 2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neuroscience Letters. 493 (3): 76–79. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.
  18. ^ González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. (March 2008). "Identification of a serotonin/glutamate receptor complex implicated in psychosis". Nature. 452 (7183): 93–97. Bibcode:2008Natur.452...93G. doi:10.1038/nature06612. PMC 2743172. PMID 18297054.
  19. ^ González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. (February 2007). "Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior". Neuron. 53 (3): 439–452. doi:10.1016/j.neuron.2007.01.008. PMID 17270739. S2CID 16309730.
  20. ^ Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A (2019). "Dopamine Agonists: From the 1970s to Today". Neuroendocrinology. 109 (1): 34–41. doi:10.1159/000499470. PMID 30852578.
  21. ^ Rogawski MA, Aghajanian GK (1979). "Response of central monoaminergic neurons to lisuride: comparison with LSD". Life Sci. 24 (14): 1289–1297. doi:10.1016/0024-3205(79)90148-6. PMID 470543.
  22. ^ "PDSP Database - UNC". pdsp.unc.edu. Archived from the original on 13 April 2021. Retrieved 15 January 2022.
  23. ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 747–. ISBN 978-1-4757-2085-3.
  24. ^ a b c d Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 612–. ISBN 978-3-88763-075-1.
  25. ^ a b c d "Dopergin". Archived from the original on 2020-11-27.
  26. ^ Hilderbrand M, Hümpel M, Krause W, Täuber U (January 1987). "Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog". European Journal of Drug Metabolism and Pharmacokinetics. 12 (1): 31–40. doi:10.1007/BF03189859. PMID 3609071. S2CID 22838914.
  27. ^ Zikán V, Semonský M (1960). "Mutterkornalkaloide XVI. Einige N-(D-6-methylisoergolenyl-8)-, N-(D-6-methylergolenyl-8)- und N-(D-6-methylergolin(I)-yl-8)-N'-substituierte harnstoffe". Collection of Czechoslovak Chemical Communications. 25 (7): 1922–1928. doi:10.1135/cccc19601922. ISSN 0010-0765.
  28. ^ Satoskar RS, Bhandarkar SD, Rege NN (1973). "General Anesthetics". Pharmacology and Pharmacotherapeutics. Popular Prakashan. pp. 929–. ISBN 978-81-7991-527-1.
  29. ^ Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 170–. ISBN 978-0-7514-0499-9.
  30. ^ "Lisuride - Axxonis Pharma". AdisInsight. Springer Nature Switzerland AG.
  31. ^ "Lisuride implant - Titan Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Lisuride&oldid=1253440621"